Skip to main content

View full-text article in PMC

. 2023 Aug 3;14(4):e01024-23. doi: 10.1128/mbio.01024-23

TABLE 4.

Relative effectiveness of tixagevimab/cilgavimab versus untreated controls using exact matching

	Matched patients without treatment (N = 1,701)	Tixagevimab/cilgavimab-treated patients (N = 1,701)
	Matched patients without treatment (N = 1,701)	Tixagevimab/cilgavimab-treated patients (N = 1,701)			Number of events, 24-wk risk^a (95% CI)	Number of events, 24-wk risk (95% CI)
Composite outcome (SARS-CoV-2 infection, COVID-19 hospitalization, and all-cause mortality)
Overall cohort	86, 51 (41–63)	44, 26 (19–35)
Severely immunocompromised	58, 52 (35–79)	34, 30 (21–42)
Individual outcome (overall cohort)
SARS-CoV-2 infection	30, 18 (12–25)	12, 7 (4–12)
COVID-19-related hospitalization	27, 16 (11–23)	<11, 4 (2–9)^a
All-cause mortality	41, 24 (17–32)	26, 15 (10–22)
Secondary outcome (overall cohort)
Emergency department, urgent or intensive care	48, 15 (11–20)	20, 6 (4–9)

^{^a}

Exact number not shown, to protect patient information.